IRadimed Corporation (IRMD) Key Metrics
IRMD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.13B
- Enterprise value
- $1.05B
- P/E (TTM)
- 49.3 10-yr median 41.8
- Forward P/E
- 41.2
- PEG ratio
- 4.46
- Price / sales
- 13.1 10-yr median 9.1
- Price / book
- 10.9 10-yr median 6.2
- EV / EBITDA
- 36.1 10-yr median 31.8
- Dividend yield
- 0.91% $0.80 a year
- Beta
- 0.91
IRMD key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsIRMD valuation Price multiples at each fiscal year-end price.
IRMD returns How much profit the business earns on the capital it uses.
IRMD per-share figures Results divided by the shares outstanding at year-end.
IRMD financial health Debt, liquidity and how easily interest is covered.
IRMD efficiency & capital use Working capital cycle and where the cash goes.
IRMD valuation history
IRMD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
IRMD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
IRMD cash returned to shareholders
IRMD price vs earnings per share
IRMD key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.25B | $703.1M | $603.9M | $357.5M | $581.8M | $283.6M | $287.0M | $296.2M | $177.6M | $133.1M |
| Enterprise value | $1.20B | $651.0M | $556.2M | $301.7M | $521.8M | $234.4M | $243.7M | $262.0M | $152.9M | $108.8M |
| P/E ratio | 55.6 | 36.6 | 35.1 | 27.9 | 62.4 | 207.2 | 29.8 | 47.0 | 355.3 | 18.4 |
| Price / sales | 14.9 | 9.6 | 9.2 | 6.7 | 13.9 | 8.9 | 7.5 | 9.7 | 7.7 | 4.1 |
| Price / book | 13.2 | 8.1 | 8.5 | 4.9 | 8.1 | 4.6 | 5.2 | 7.1 | 5.4 | 4.2 |
| Price / free cash flow | 72.8 | 39.9 | 110.7 | 43.8 | 55.3 | 54.7 | 29.4 | 41.7 | 68.5 | 16.9 |
| Price / operating cash flow | 50.1 | 27.4 | 44.9 | 35.6 | 51.7 | 48.8 | 28.0 | 40.2 | 52.0 | 14.1 |
| EV / sales | 14.3 | 8.9 | 8.5 | 5.7 | 12.5 | 7.4 | 6.3 | 8.6 | 6.6 | 3.3 |
| EV / EBITDA | 40.6 | 25.9 | 27.8 | 18.5 | 46.4 | 402.2 | 24.6 | 35.9 | 56.5 | 9.7 |
| EV / free cash flow | 69.8 | 36.9 | 101.9 | 36.9 | 49.6 | 45.2 | 25.0 | 36.8 | 59.0 | 13.8 |
| Earnings yield | 1.8% | 2.7% | 2.8% | 3.6% | 1.6% | 0.5% | 3.4% | 2.1% | 0.3% | 5.4% |
| Free cash flow yield | 1.4% | 2.5% | 0.9% | 2.3% | 1.8% | 1.8% | 3.4% | 2.4% | 1.5% | 5.9% |
| Dividend yield | 1.2% | 1.9% | 2.2% | 3.5% | 2.2% | 4.4% | 4.4% | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 1.2% | 1.9% | 2.3% | 3.5% | 2.3% | 4.9% | 4.5% | 0.1% | 1.0% | 7.5% |
| Share price at fiscal year-end | $97.28 | $55.00 | $47.47 | $28.29 | $46.21 | $22.80 | $23.38 | $24.46 | $15.15 | $11.10 |
| Per share | ||||||||||
| Revenue per share | $6.52 | $5.73 | $5.15 | $4.22 | $3.32 | $2.55 | $3.14 | $2.51 | $1.97 | $2.71 |
| Earnings per share | $1.75 | $1.50 | $1.35 | $1.02 | $0.74 | $0.11 | $0.78 | $0.52 | $0.04 | $0.60 |
| Operating cash flow per share | $1.94 | $2.00 | $1.06 | $0.79 | $0.89 | $0.47 | $0.83 | $0.61 | $0.29 | $0.78 |
| Free cash flow per share | $1.34 | $1.38 | $0.43 | $0.65 | $0.84 | $0.42 | $0.79 | $0.59 | $0.22 | $0.66 |
| Cash per share | $3.98 | $4.09 | $3.91 | $4.59 | $4.96 | $4.18 | $3.77 | $2.84 | $2.25 | $2.14 |
| Book value per share | $7.36 | $6.79 | $5.61 | $5.83 | $5.73 | $4.93 | $4.52 | $3.46 | $2.81 | $2.66 |
| Tangible book value per share | $7.10 | $6.55 | $5.42 | $5.67 | $5.64 | $4.86 | $4.45 | $3.39 | $2.73 | $2.58 |
| Dividends per share | $1.17 | $1.07 | $1.04 | $0.99 | $1.00 | $1.01 | $1.02 | — | $0.00 | $0.00 |
| Capex per share | $0.60 | $0.63 | $0.63 | $0.15 | $0.06 | $0.05 | $0.04 | $0.02 | $0.07 | $0.13 |
| Debt per share | — | $0.01 | $0.16 | $0.17 | $0.20 | $0.22 | $0.24 | $0.01 | $0.14 | $0.12 |
| Shares outstanding | 12.9M | 12.8M | 12.7M | 12.6M | 12.6M | 12.4M | 12.3M | 12.1M | 11.7M | 12.0M |
| Change in shares outstanding | +0.6% | +0.5% | +0.7% | +0.4% | +1.2% | +1.3% | +1.4% | +3.3% | −2.2% | −4.5% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 24.8% | 24.3% | 23.7% | 17.6% | 14.0% | 2.3% | 19.8% | 16.8% | 1.5% | 22.6% |
| Return on invested capital (ROIC) | 53.0% | 59.6% | 76.1% | 82.4% | 76.7% | −4.9% | 86.8% | 75.1% | 8.1% | 114.3% |
| Return on assets (ROA) | 21.7% | 20.2% | 19.4% | 15.2% | 12.1% | 2.0% | 16.7% | 14.4% | 1.3% | 19.9% |
| Return on tangible assets | 21.3% | 20.2% | 19.2% | 15.4% | 11.4% | 2.0% | 14.6% | 13.2% | 1.3% | 19.9% |
| Free cash flow margin | 20.5% | 24.1% | 8.3% | 15.3% | 25.2% | 16.3% | 25.3% | 23.4% | 11.2% | 24.3% |
| Income quality (OCF / net income) | 1.11 | 1.33 | 0.78 | 0.78 | 1.21 | 4.25 | 1.06 | 1.17 | 6.84 | 1.30 |
| Financial health | ||||||||||
| Total debt | — | $154,688 | $2.0M | $2.2M | $2.5M | $2.7M | $3.0M | $133,000 | $1.7M | $1.4M |
| Cash & short-term investments | $51.2M | $52.2M | $49.8M | $58.0M | $62.5M | $52.0M | $46.3M | $34.4M | $26.3M | $25.7M |
| Net debt | −$51.2M | −$52.1M | −$47.7M | −$55.8M | −$60.0M | −$49.3M | −$43.3M | −$34.2M | −$24.6M | −$24.3M |
| Debt / equity | — | 0.00 | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 | 0.00 | 0.05 | 0.04 |
| Debt / assets | — | 0.00 | 0.02 | 0.03 | 0.03 | 0.04 | 0.04 | 0.00 | 0.04 | 0.04 |
| Net debt / EBITDA | −1.73 | −2.08 | −2.38 | −3.42 | −5.34 | −84.54 | −4.38 | −4.69 | −9.11 | −2.18 |
| Current ratio | 7.98 | 8.84 | 4.65 | 9.06 | 11.18 | 12.96 | 10.06 | 9.50 | 8.61 | 9.33 |
| Quick ratio | 6.84 | 7.62 | 3.87 | 8.43 | 10.54 | 12.16 | 9.44 | 8.63 | 7.58 | 8.27 |
| Interest coverage | — | — | — | 26.9 | 527.7 | -5.4 | 21.8 | — | — | — |
| Working capital | $71.0M | $66.7M | $59.7M | $68.9M | $69.4M | $58.8M | $53.1M | $39.9M | $31.0M | $30.5M |
| Invested capital | $43.5M | $34.7M | $23.7M | $17.9M | $12.2M | $12.1M | $12.2M | $7.7M | $8.3M | $7.6M |
| Tangible asset value | $91.2M | $83.7M | $68.9M | $71.6M | $71.1M | $60.4M | $54.7M | $41.1M | $32.0M | $31.0M |
| Net current asset value | $67.0M | $63.7M | $55.3M | $65.6M | $65.5M | $54.1M | $47.8M | $38.0M | $29.0M | $28.9M |
| Graham number | $17.02 | $15.16 | $13.06 | $11.54 | $9.77 | $3.50 | $8.94 | $6.37 | $1.64 | $6.00 |
| Graham net-net per share | $4.13 | $4.21 | $3.51 | $4.65 | $4.59 | $3.83 | $3.45 | $2.73 | $2.15 | $2.10 |
| Capital allocation | ||||||||||
| Dividends paid | $15.0M | $13.7M | $13.2M | $12.6M | $12.6M | $12.6M | $12.6M | — | $0 | $0 |
| Share buybacks (net) | — | — | $610,348 | $0 | $598,817 | $1.2M | $473,143 | $309,561 | $1.8M | $10.0M |
| Dividend payout ratio | 66.9% | 71.1% | 76.9% | 97.9% | 134.7% | 917.4% | 130.4% | — | 0.0% | 0.0% |
| Dividends + buybacks / free cash flow | 87.5% | 77.6% | 253.5% | 153.8% | 125.1% | 265.7% | 133.7% | 4.4% | 70.2% | 126.5% |
| Capex / revenue | 9.3% | 10.9% | 12.2% | 3.5% | 1.8% | 2.0% | 1.3% | 0.9% | 3.6% | 4.7% |
| Capex / operating cash flow | 31.1% | 31.2% | 59.5% | 18.7% | 6.6% | 10.9% | 4.7% | 3.6% | 24.1% | 16.2% |
| Capex / depreciation | 6.66 | 9.79 | 10.46 | 2.80 | 0.53 | 0.48 | 0.39 | 0.24 | 0.63 | 6.14 |
| Stock-based compensation / revenue | 3.5% | 3.4% | 3.3% | 2.6% | 3.5% | 12.5% | 4.8% | 5.8% | 10.6% | 5.7% |
| R&D / revenue | 3.5% | 3.9% | 4.4% | 4.3% | 4.6% | 6.0% | 3.7% | 5.0% | 7.5% | 4.1% |
| SG&A / revenue | 42.0% | 43.1% | 41.6% | 43.9% | 48.6% | 70.7% | 50.9% | 51.6% | 62.8% | 43.3% |
| Efficiency | ||||||||||
| Days sales outstanding | 52.7 | 56.8 | 71.0 | 63.0 | 42.4 | 68.3 | 54.5 | 47.9 | 59.7 | 42.9 |
| Days of inventory on hand | 206.2 | 250.9 | 215.5 | 146.8 | 153.9 | 169.8 | 159.4 | 209.3 | 265.3 | 185.9 |
| Days payables outstanding | 34.8 | 40.6 | 43.3 | 39.2 | 26.9 | 37.0 | 36.6 | 36.2 | 58.2 | 63.0 |
| Cash conversion cycle (days) | 224.2 | 267.1 | 243.2 | 170.6 | 169.4 | 201.1 | 177.4 | 221.0 | 266.8 | 165.8 |
| Receivables turnover | 6.92 | 6.43 | 5.14 | 5.79 | 8.61 | 5.34 | 6.70 | 7.62 | 6.11 | 8.51 |
| Payables turnover | 10.49 | 9.00 | 8.43 | 9.31 | 13.56 | 9.87 | 9.98 | 10.09 | 6.27 | 5.79 |
| Inventory turnover | 1.77 | 1.45 | 1.69 | 2.49 | 2.37 | 2.15 | 2.29 | 1.74 | 1.38 | 1.96 |
| Asset turnover | 0.81 | 0.77 | 0.74 | 0.63 | 0.54 | 0.46 | 0.67 | 0.70 | 0.61 | 0.90 |
| Average receivables | $12.1M | $11.4M | $12.7M | $9.2M | $4.9M | $5.9M | $5.8M | $4.0M | $3.8M | $3.8M |
| Average payables | $1.9M | $1.9M | $1.8M | $1.3M | $719,978 | $825,398 | $883,106 | $714,596 | $888,776 | $1.1M |
| Average inventory | $11.0M | $11.6M | $9.1M | $4.8M | $4.1M | $3.8M | $3.9M | $4.1M | $4.0M | $3.1M |
| Intangibles / total assets | 3.1% | 3.2% | 2.7% | 2.4% | 1.3% | 1.4% | 1.3% | 1.7% | 2.3% | 2.5% |
Computed from IRMD's annual financial statements (latest annual report filed March 6, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
IRMD valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), IRadimed traded at 55.6 times earnings, against a 10-year median of 41.8. Based on the latest twelve months, the trailing P/E is 49.3 and the forward P/E is 41.2. IRadimed earned a return on equity of 24.8% and a return on invested capital of 53.0% in fiscal 2025. It returned $15.0 million to shareholders: $15.0 million in dividends and $0 in share buybacks, 88% of free cash flow. The share count rose 7.2% from 12.0M to 12.9M over 9 years.
See the IRMD income statement, the IRMD chart for price history, or the IRMD stock overview for the latest quote and news.
IRMD key metrics FAQ
What is IRadimed's P/E ratio?
IRadimed's trailing P/E ratio is 49.3 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 41.2. At the end of fiscal 2025 it was 55.6, compared with a 10-year median of 41.8.
What is IRadimed's EV/EBITDA?
IRadimed's enterprise value was 40.6 times EBITDA at the end of fiscal 2025 (enterprise value $1.2 billion, EBITDA $29.5 million); the current EV/EBITDA is 36.1.
What is IRadimed's return on equity?
IRadimed's return on equity (ROE) was 24.8% in fiscal 2025: net income of $22.5 million on average shareholders' equity of $90.7 million.
What is IRadimed's ROIC?
IRadimed's return on invested capital was 53.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is IRadimed's dividend yield?
IRadimed's forward dividend yield is 0.91%. IRadimed paid $15.0 million in dividends in fiscal 2025 ($1.17 per share), a payout ratio of 66.9%.
What is IRadimed's free cash flow yield?
IRadimed generated $17.2 million of free cash flow in fiscal 2025, a free cash flow yield of 1.4% on its market value at year-end ($1.3 billion).
What is IRadimed's current ratio?
IRadimed's current ratio was 7.98 at the end of fiscal 2025: current assets were 7.98 times current liabilities.